DEALS: Novartis expands OTC operations

Novartis wins big OTC deal.







Bristol-Myers Squibb

$660 million acquisition of US and Canadian OTC division

Novartis gains rights to a broad range of OTC drugs, including Excedrin and Comtrex.



$269 million buyout

Omnicare gains a provider of comprehensive pharmaceutical care services, primarily for hospice patients.


D&K Healthcare Resources

$207 million buyout

McKesson adds a regional drug distributor to its operations.



$187.4 million buyout

The deal expands Sosei's pipeline with several compounds in development, including a $375 million global partnership with Novartis for its lead product AD 237.


Quintiles Transnational

$125 million business unit acquisition

The units will be reorganized by Aptuit into three global business lines: Preclinical Technologies, Pharmaceutical Sciences and Packaging & Logistics.

Roche Group

GlycArt Biotechnology


Roche gains new technology technology for enhancing the efficacy of antibodies.

American Pacific

Aerojet Fine Chemicals

Buyout for $119 million plus liabilities

American Pacific buys an established player in the sale of active pharmaceutical ingredients.

Assay Designs

Stressgen Bioreagents


Stressgen develops and markets antibodies, proteins and related kits to life sciences researchers worldwide.

Hi-Tech Pharmacal

Rodlen Laboratories

$4.4 million brand buyout

Hi-Tech gains control of Zostrix OTC analgesic creams.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.